The primary goals of the Gastrointestinal (GI) Disease Management Group are to provide cutting-edge multidisciplinary care for patients and to advance the clinical and basic science behind GI malignancies.
This group is includes leadership  from:
- Experienced and nationally prominent GI medical and radiation oncologists
- Gastroenterologists who have expertise in GI cancer and advanced endoscopic procedures
- Surgical oncologists dedicated to GI procedures
- Translational scientists whose research on GI malignancies is funded by the National Institutes of Health.
GI malignancies include cancers of the esophagus, stomach, liver, gallbladder, biliary ducts, pancreas, small bowel, colon, rectum, and anal canal. Each area has a separate biology, molecular biology, etiology and therapy that require specialized knowledge from the treating physician. Because some GI cancers have a hereditary component, genetic counseling is an important part of the GI Disease Management Group.
Many patients with GI malignancies need treatment from different specialists. This group coordinates those specialists into a team approach centered on each patient.
Research  in the GI Group is focused on translating the work of its basic scientists into real-time therapy for patients. The group uses the strengths of its clinic and bench scientists to develop new treatments for patients and to influence therapy for GI cancers throughout the world. Researchers here participate in and lead national clinical trials for patients with GI cancers.
Leaders of the GI Disease Management Group hold key roles in the NCI-Task Forces on Rectal and UGI Malignancies and also in the Eastern Cooperative Oncology Group (ECOG) and SWOG (formerly the Southwest Oncology Group). They are also participants in the Academic Gastrointestinal Cancer Consortium, an organization of GI cancer experts who are conducting translational trials in GI malignancies.